On May 13, 2025, Connect Biopharma Holdings Ltd announced the start of its Phase 2 Seabreeze STAT Asthma study after receiving FDA approval for the study protocol, targeting asthma treatment with expected topline data in the first half of 2026.
AI Assistant
CONNECT BIOPHARMA HOLDINGS LTD
2025
8 K
Find Answers
Ask about any part of the document to get insights, explanations, or key details.